Press Releases

March 5 2014

Many of the provisions included in this budget proposal would jeopardize the continued biotech...

January 30 2014

Patients Should Be Informed if Doctor's Prescription Changed

January 14 2014

Spending plan would enable the FDA to access $85 million in sequestered user fees

November 18 2013

BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.

November 13 2013

The Bill will spur capital formation for small public companies

November 6 2013

Bill will encourage investment in growing innovative companies

October 13 2013

Despite overwhelming bipartisan approval, California Governor Jerry Brown vetoed legislation...

August 21 2013

BIO applauds Rep. Michael Burgess (R-TX) and Rep. Jackie Speier (D-CA) for introducing the...

August 1 2013

S. 1413 and H.R. 2725 would exempt future FDA user fees from sequestration.

July 10 2013

H.R. 2629 will cut compliance costs for innovative emerging biotech companies

July 10 2013

Chimerix President and CEO emphasizes the role of the public market to help finance critical R...

June 10 2013

BIO and Delaware Biocommend the State Senate for introducing legislation designed to ...

June 7 2013

Oregon Governor John Kitzhaber signed legislation on Thursday, June 6 designed to address the...

June 5 2013

House Bill 365, signed by Governor Rick Scott, contains four of BIO’s five principles on...

June 3 2013

Florida's repeal of the state Renewable Fuel Standard could chill investment, innovation...

May 14 2013

BIO welcomes the unanimous Supreme Court decision in Bowman v. Monsanto, in which the Court...

April 23 2013

The Biotechnology Industry Organization (BIO) released its “Bioscience Economic...

April 16 2013

Bill would allow emerging biotech companies to maintain a working relationship with their...

April 11 2013

BIO stands ready to work with the Administration to develop policies that help spur innovation...

April 3 2013

The Biotechnology Industry Organization (BIO) and ...

March 21 2013

In statehouses around the country, lawmakers are beginning to address the complexities of...

October 9 2012

Any waiver of the RFS would have little to no effect on corn prices, but would certainly harm...

September 25 2012

Bill would stimulate capital formation for small biotech companies.

July 27 2012

The measure forces certain companies to pay for disposal.

June 19 2012

Fifth biennial report by Battelle outlines 6.4% job growth in sector from 2001 to 2010, while...

June 14 2012

Support Of Industry Underscores Pro-Business Commitment

June 6 2012

The report will be released at a Super Session, titled "International Leaders Share Their...

April 26 2012

BIO today thanked Sens. Richard Lugar (R-Ind.), Kent Conrad (D-N.D.), and nine others...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Michael...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Kay...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Robert...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

April 17 2012

The Biotechnology Industry Organization (BIO) submitted comments yesterday to the U.S. Food...

March 2 2012

The Biotechnology Industry Organization (BIO) announced today that it has integrated its...

February 9 2012

BIO President and CEO Jim Greenwood issued the following statement regarding the newly...

January 25 2012

BIO calls on the administration and Congress to embrace proposals to Unleash the Promise of...

November 16 2011

"The most important return on investment from this initiative would be the creation of...

November 2 2011

The Small Company Capital Formation Act (HR 1070) passed today by a vote of 421-1.

October 26 2011

 BIO Commends Governor Nixon and Missouri Legislature for Commitment to Industry

October 13 2011

BIO President and CEO Jim Greenwood released the following statement on the Obama...

October 5 2011

BIO welcomed the transmission of the Korea-U.S. Free Trade Agreement (KORUS FTA) by President...

September 9 2011

BIO President and CEO Jim Greenwood released the following statement on President Obama’...

September 8 2011

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

September 1 2011

Research and development in synthetic biology is an evolution of biotechnology innovation that...

September 1 2011

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

July 27 2011

BIO praised today’s ruling by a U.S. District Court dismissing a lawsuit that sought to...

June 29 2011

“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease...

May 4 2011

The Biotechnology Industry Organization (BIO) announced today its selection of Congressman...

April 28 2011

During BIO's 8th annual World Congress on Industrial Biotechnology and Bioprocessing,...

April 21 2011

Corporate leaders will discuss benefits for businesses and consumers through incorporation of...

April 14 2011

Business executives, scientists and policy makers will highlight opportunities to...

April 6 2011

BIO announces the hires of Sarah Thornton as director of biofuels and biomass policy and...

March 31 2011

BIO announces the industrial biotechnology companies selected to present their technology...

March 21 2011

Industry analysts are projecting double digit growth in the biobased product sector, and an...

March 7 2011

Company C-level executives, scientists and government officials from Canada, Europe and the...

March 2 2011

The 2011 BIO International Convention will feature six high-level super sessions focused on...

February 22 2011

BIO issues statement commending today’s ruling by the U.S. Supreme Court in ...

February 9 2011

BIO and several of its member companies will offer input on progress and potential adjustments...

January 13 2011

More than 1,000 high-profile scientists, executives, government officials and investors are...

May 24 2010

Achievement of a milestone in creating synthetic life in the form of a self-replicating cell...

July 30 2008

Small businesses that are majority-backed by venture capital, many of which are producing...

July 25 2007

The Biotechnology Industry Organization (BIO) today launched a new program, Excellence Through...

September 20 2006

The Milken Institute study released today entitled “Mind-to-Market: A Global Analysis of...

September 13 2006

Jim Greenwood issued the following remarks regarding comments submitted Tuesday by BIO and a...

July 11 2006

Jim Greenwood issued the following statement in response to the Securities and Exchange...

June 30 1999

 The American Hospital Association and BIO have signed a memorandum of understanding to...

February 19 1999
March 27 2014
February 25, 2013     Marilyn Tavenner, B.S.N., M.H.A. Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201   Re: Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces   Dear Ms. Tavenner:             The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the draft letter related to the Patient Protection and Affordable Care Act’s (ACA) health insurance Marketplaces that the Centers for Medicare & Medicaid Services (CMS) issued on February 4, 2014, entitled “Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces” (the “Draft Letter”).[1]             BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced health care expenditures due to fewer physician office visits, hospitalizations, and surgical interventions. [1] Center for Consumer Information and Insurance Oversight (CCIIO), Centers for Medicare & Medicaid Services (CMS), Draft 2015 Letter to Issuers in the Federally-facilitated Marketplaces (FFM) (Feb. 4, 2014). Available at: http://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/draft-issuer-letter-2-4-2014.pdf (hereinafter “Draft Letter to Issuers”).   
March 27 2014
VIA ELECTRONIC SUBMISSION   March 1, 2014     Patrick Conway, M.D. Deputy Administrator for Innovation and Quality Chief Medical Officer Centers for Medicare & Medicaid Services Center for Medicare and Medicaid Innovation 7500 Security Boulevard Baltimore, MD 21244   RE: Request for Information: Evolution of ACO Initiatives at CMS   Dear Dr. Conway:   The Biotechnology Industry Organization (BIO) is pleased to submit the following comments regarding the Request for Information (RFI) on the “Evolution of ACO Initiatives at CMS” released by the Center for Medicare and Medicaid Innovation (CMMI) on December 20, 2013.[1]  BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations.  BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place.  In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions. [1]           Center for Medicare and Medicaid Innovation, Request for Information: Evolution of ACO Initiatives at CMS (Dec. 20, 2013), available at: http://innovation.cms.gov/Files/x/Pioneer-RFI.pdf.   
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
April 10 2014
BIO and Delaware Bio commend the Delaware State Senate for unanimously passing legislation yesterday designed to create a pathway for the substitution of interchangeable biologic medicines. 
March 5 2014
Many of the provisions included in this budget proposal would jeopardize the continued biotech research and development that is necessary to find cures and breakthrough medicines for patients living with debilitating and life-threatening diseases. 
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed
January 14 2014
Spending plan would enable the FDA to access $85 million in sequestered user fees
November 18 2013
BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.